Liraglutide and Recurrent Stroke by Baseline Insulin Resistance: A Post Hoc Analysis of the LAMP Trial.

Lu L, Yang B, Wang Y, Zhu C, Liu Z, Li F, Yang S, Liu Y, Yang Y, Liu X, Huang L, Xu A, Zhu H

Stroke18 May 2026

PMID42145088PMCIDPMC13281981DOI10.1161/strokeaha.125.056010PepBankPUB-42145088

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialOther
In 510 patients with type 2 diabetes and minor ischemic stroke or high-risk transient ischemic attack, adding liraglutide to standard therapy versus standard therapy alone had a treatment-by-insulin-resistance interaction for stroke recurrence (P for interaction=0.02).
In plain wordsIn people with type 2 diabetes after stroke/TIA, liraglutide-versus-standard-therapy stroke results differed by insulin resistance.
Peptide
Liraglutide
Outcome
Direction not reportedTreatment-by-insulin-resistance interaction for stroke recurrence
Study
n = 510
Comparator
Standard therapy alone
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Measurements
P for interaction
0.02
stroke recurrence
Source sentences
Summary
A significant interaction between treatment and insulin resistance was observed for both stroke recurrence and composite vascular events (P for interaction=0.02 for both).
6 context sentences(design, population, supporting numbers)
Summary · context
a multicenter, open-label, randomized controlled trial conducted at 27 hospitals in China between June 25, 2019, and December 27, 2023) included patients with minor ischemic stroke or high-risk transient ischemic attack and type 2 diabetes.
Summary · context
Participants were randomized (1:1) to liraglutide plus standard therapy or standard therapy alone.
Summary · context
IR was assessed using the homeostasis model assessment of IR, with a cutoff of 2.5 based on prior studies in Asian populations.
Summary · context
Treatment-by-IR interactions were evaluated using Cox models.
Summary · context
Absolute risk reduction was calculated as the difference in event rates between groups and was based on crude estimates.
Summary · context
Among 636 enrolled patients, 510 were included in this analysis (mean age, 65 years; 64.7% male; follow-up, 3 months).
Report a problemFND-4214508805
02HumanRandomized controlled trialOther
In 510 patients with type 2 diabetes and minor ischemic stroke or high-risk transient ischemic attack, adding liraglutide to standard therapy versus standard therapy alone had a treatment-by-insulin-resistance interaction for composite vascular events (P for interaction=0.02).
In plain wordsIn people with type 2 diabetes after stroke/TIA, liraglutide-versus-standard-therapy vascular-event results differed by insulin resistance.
Peptide
Liraglutide
Outcome
Direction not reportedTreatment-by-insulin-resistance interaction for composite vascular events
Study
n = 510
Comparator
Standard therapy alone
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Measurements
P for interaction
0.02
composite vascular events
Source sentences
Summary
A significant interaction between treatment and insulin resistance was observed for both stroke recurrence and composite vascular events (P for interaction=0.02 for both).
6 context sentences(design, population, supporting numbers)
Summary · context
a multicenter, open-label, randomized controlled trial conducted at 27 hospitals in China between June 25, 2019, and December 27, 2023) included patients with minor ischemic stroke or high-risk transient ischemic attack and type 2 diabetes.
Summary · context
Participants were randomized (1:1) to liraglutide plus standard therapy or standard therapy alone.
Summary · context
IR was assessed using the homeostasis model assessment of IR, with a cutoff of 2.5 based on prior studies in Asian populations.
Summary · context
Treatment-by-IR interactions were evaluated using Cox models.
Summary · context
Absolute risk reduction was calculated as the difference in event rates between groups and was based on crude estimates.
Summary · context
Among 636 enrolled patients, 510 were included in this analysis (mean age, 65 years; 64.7% male; follow-up, 3 months).
Report a problemFND-4214508806
03HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes and minor ischemic stroke or high-risk transient ischemic attack with HOMA-IR at least 2.5, liraglutide reduced stroke recurrence versus standard therapy alone (5.8% versus 18.1%; absolute risk reduction 12.3%, 95% CI 5.6%-19.0%; number needed to treat 8).
In plain wordsIn people with type 2 diabetes and higher insulin resistance after stroke or TIA, liraglutide reduced recurrent stroke versus standard therapy.
Peptide
Liraglutide
Outcome
DecreaseStroke recurrence in patients with HOMA-IR at least 2.5
Study
n: not reported in source
Comparator
Standard therapy alone
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Measurements
Stroke recurrence
5.8%
liraglutide
Stroke recurrence
18.1%
standard therapy alone
Absolute risk reduction
12.3%
95% CI 5.6%-19.0%
Number needed to treat
8
stroke recurrence
Source sentences
Summary
Among patients with homeostasis model assessment of IR ≥2.5, liraglutide reduced stroke recurrence (5.8% versus 18.1%; absolute risk reduction, 12.3% [95% CI, 5.6%-19.0%]; number needed to treat=8) and vascular events (5.8% versus 19.2%; absolute risk reduction, 13.4% [95% CI, 6.6%-20.2%]; number needed to treat=8).
6 context sentences(design, population, supporting numbers)
Summary · context
a multicenter, open-label, randomized controlled trial conducted at 27 hospitals in China between June 25, 2019, and December 27, 2023) included patients with minor ischemic stroke or high-risk transient ischemic attack and type 2 diabetes.
Summary · context
Participants were randomized (1:1) to liraglutide plus standard therapy or standard therapy alone.
Summary · context
IR was assessed using the homeostasis model assessment of IR, with a cutoff of 2.5 based on prior studies in Asian populations.
Summary · context
Treatment-by-IR interactions were evaluated using Cox models.
Summary · context
Absolute risk reduction was calculated as the difference in event rates between groups and was based on crude estimates.
Summary · context
Among 636 enrolled patients, 510 were included in this analysis (mean age, 65 years; 64.7% male; follow-up, 3 months).
Report a problemFND-4214508801
04HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes and minor ischemic stroke or high-risk transient ischemic attack with HOMA-IR at least 2.5, liraglutide reduced vascular events versus standard therapy alone (5.8% versus 19.2%; absolute risk reduction 13.4%, 95% CI 6.6%-20.2%; number needed to treat 8).
In plain wordsIn people with type 2 diabetes and higher insulin resistance after stroke or TIA, liraglutide reduced vascular events versus standard therapy.
Peptide
Liraglutide
Outcome
DecreaseComposite vascular events in patients with HOMA-IR at least 2.5
Study
n: not reported in source
Comparator
Standard therapy alone
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Measurements
Vascular events
5.8%
liraglutide
Vascular events
19.2%
standard therapy alone
Absolute risk reduction
13.4%
95% CI 6.6%-20.2%
Number needed to treat
8
vascular events
Source sentences
Summary
Among patients with homeostasis model assessment of IR ≥2.5, liraglutide reduced stroke recurrence (5.8% versus 18.1%; absolute risk reduction, 12.3% [95% CI, 5.6%-19.0%]; number needed to treat=8) and vascular events (5.8% versus 19.2%; absolute risk reduction, 13.4% [95% CI, 6.6%-20.2%]; number needed to treat=8).
6 context sentences(design, population, supporting numbers)
Summary · context
a multicenter, open-label, randomized controlled trial conducted at 27 hospitals in China between June 25, 2019, and December 27, 2023) included patients with minor ischemic stroke or high-risk transient ischemic attack and type 2 diabetes.
Summary · context
Participants were randomized (1:1) to liraglutide plus standard therapy or standard therapy alone.
Summary · context
IR was assessed using the homeostasis model assessment of IR, with a cutoff of 2.5 based on prior studies in Asian populations.
Summary · context
Treatment-by-IR interactions were evaluated using Cox models.
Summary · context
Absolute risk reduction was calculated as the difference in event rates between groups and was based on crude estimates.
Summary · context
Among 636 enrolled patients, 510 were included in this analysis (mean age, 65 years; 64.7% male; follow-up, 3 months).
Report a problemFND-4214508802
05HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes and minor ischemic stroke or high-risk transient ischemic attack with HOMA-IR below 2.5, liraglutide did not significantly reduce recurrent stroke versus standard therapy alone.
In plain wordsIn people with type 2 diabetes and lower insulin resistance after stroke or TIA, liraglutide did not significantly reduce recurrent stroke versus standard therapy.
Peptide
Liraglutide
Outcome
No significant changeStroke recurrence in patients with HOMA-IR below 2.5
Study
n: not reported in source
Comparator
Standard therapy alone
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
No significant benefit was observed in those with homeostasis model assessment of IR <2.5.
6 context sentences(design, population, supporting numbers)
Summary · context
a multicenter, open-label, randomized controlled trial conducted at 27 hospitals in China between June 25, 2019, and December 27, 2023) included patients with minor ischemic stroke or high-risk transient ischemic attack and type 2 diabetes.
Summary · context
Participants were randomized (1:1) to liraglutide plus standard therapy or standard therapy alone.
Summary · context
IR was assessed using the homeostasis model assessment of IR, with a cutoff of 2.5 based on prior studies in Asian populations.
Summary · context
Treatment-by-IR interactions were evaluated using Cox models.
Summary · context
Absolute risk reduction was calculated as the difference in event rates between groups and was based on crude estimates.
Summary · context
Among 636 enrolled patients, 510 were included in this analysis (mean age, 65 years; 64.7% male; follow-up, 3 months).
Report a problemFND-4214508803
06HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes and minor ischemic stroke or high-risk transient ischemic attack with HOMA-IR below 2.5, liraglutide did not significantly reduce vascular events versus standard therapy alone.
In plain wordsIn people with type 2 diabetes and lower insulin resistance after stroke or TIA, liraglutide did not significantly reduce vascular events versus standard therapy.
Peptide
Liraglutide
Outcome
No significant changeComposite vascular events in patients with HOMA-IR below 2.5
Study
n: not reported in source
Comparator
Standard therapy alone
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
No significant benefit was observed in those with homeostasis model assessment of IR <2.5.
6 context sentences(design, population, supporting numbers)
Summary · context
a multicenter, open-label, randomized controlled trial conducted at 27 hospitals in China between June 25, 2019, and December 27, 2023) included patients with minor ischemic stroke or high-risk transient ischemic attack and type 2 diabetes.
Summary · context
Participants were randomized (1:1) to liraglutide plus standard therapy or standard therapy alone.
Summary · context
IR was assessed using the homeostasis model assessment of IR, with a cutoff of 2.5 based on prior studies in Asian populations.
Summary · context
Treatment-by-IR interactions were evaluated using Cox models.
Summary · context
Absolute risk reduction was calculated as the difference in event rates between groups and was based on crude estimates.
Summary · context
Among 636 enrolled patients, 510 were included in this analysis (mean age, 65 years; 64.7% male; follow-up, 3 months).
Report a problemFND-4214508804

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownNot applicableNCT03948347

Liraglutide in Acute Minor Ischemic Stroke or High-risk Transient Ischemic Attack Patients With Type 2 Diabetes Mellitus

First Affiliated Hospital of Jinan Universityn = 1,70825 Jun 2019 to est. Jun 2024

Ischemic Stroke · Transient Ischemic Attack · Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 6 Feb 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.